Replies to post #44748 on Biotech Values

[quantumdot]

>Recent growth in Avastin is coming entirely from off-label uses in lung and breast cancer.<

And off-label use in AMD but they won't be mentioning that!

[DewDiligence]

Avastin clarification:

Avastin use in lung cancer (both on-label and off-label) is growing in terms of the number of patients. However, $ sales are stagnant at best in the on-label setting because more and more oncs are treating patients with half the approved dose (7/5mg/kg instead of 15mg/kg) as a result of the data in the AVAIL trial (#msg-17277608, #msg-17353810).